- Home
- CRVO vs CVM Comparison
CRVO vs CVM Comparison
Compare CRVO & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- CVM
- Stock Information
- Founded
- CRVO 2001
- CVM 1983
- Country
- CRVO United States
- CVM United States
- Employees
- CRVO N/A
- CVM 44
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRVO Health Care
- CVM Health Care
- Exchange
- CRVO Nasdaq
- CVM Nasdaq
- Market Cap
- CRVO 67.4M
- CVM 60.9M
- IPO Year
- CRVO N/A
- CVM 1987
- Fundamental
- Price
- CRVO $7.45
- CVM $9.12
- Analyst Decision
- CRVO Strong Buy
- CVM
- Analyst Count
- CRVO 6
- CVM 0
- Target Price
- CRVO $19.17
- CVM N/A
- AVG Volume (30 Days)
- CRVO 109.4K
- CVM 82.9K
- Earning Date
- CRVO 11-11-2025
- CVM 08-14-2025
- Dividend Yield
- CRVO N/A
- CVM N/A
- EPS Growth
- CRVO N/A
- CVM N/A
- EPS
- CRVO N/A
- CVM N/A
- Revenue
- CRVO $7,776,968.00
- CVM N/A
- Revenue This Year
- CRVO N/A
- CVM N/A
- Revenue Next Year
- CRVO N/A
- CVM N/A
- P/E Ratio
- CRVO N/A
- CVM N/A
- Revenue Growth
- CRVO N/A
- CVM N/A
- 52 Week Low
- CRVO $1.80
- CVM $1.98
- 52 Week High
- CRVO $16.94
- CVM $32.70
- Technical
- Relative Strength Index (RSI)
- CRVO 38.31
- CVM 46.34
- Support Level
- CRVO $7.03
- CVM $8.61
- Resistance Level
- CRVO $8.38
- CVM $10.24
- Average True Range (ATR)
- CRVO 0.54
- CVM 0.68
- MACD
- CRVO -0.10
- CVM -0.13
- Stochastic Oscillator
- CRVO 11.00
- CVM 20.50
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.